Anti-p40 immunglobulin derived proteins, compositions, methods and uses

An isolated nucleic acid encoding at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8.

A composition comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8, and at least one pharmaceutically acceptable carrier or diluent.

An anti-idiotype antibody or fragment that specifically binds at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8.

A method for diagnosing or treating a IL-12 related condition in a cell, tissue, organ or animal, comprising

• (a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8, with, or to, said cell, tissue, organ or animal.

A medical device, comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8, wherein said device is suitable to contacting or administerting said at least one anti-p40 Ig derived protein by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8.

A method for producing at least one isolated mammalian anti-p40 Ig derived protein having at least one variable region comprising SEQ ID NO:7 or 8, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said Ig derived protein.

At least one isolated mammalian anti-p40 Ig derived protein, comprising either (i) all of the heavy chain complementarity determining regions (CDR) amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12.

An isolated nucleic acid encoding at least one isolated mammalian anti-p40 Ig derived protein either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12.

A composition comprising at least one isolated mammalian anti-p40 Ig derived protein having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12, and at least one pharmaceutically acceptable carrier or diluent.

An anti-idiotype antibody or fragment that specifically binds at least one isolated mammalian anti-p40 Ig derived protein having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12.

A medical device, comprising at least one isolated mammalian anti-p40 Ig derived protein having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12, wherein said device is suitable to contacting or administerting said at least one anti-p40 Ig derived protein by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-p40 Ig derived protein having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12.

A method for producing at least one isolated mammalian anti-p40 Ig derived protein having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:

• 7, 8, and 9;
• or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:
• 10, 11, and 12, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said Ig derived protein.

At least one isolated mammalian anti-p40 Ig derived protein, comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

An isolated nucleic acid encoding at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A composition comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, and at least one pharmaceutically acceptable carrier or diluent.

An anti-idiotype antibody or fragment that specifically binds at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A method for diagnosing or treating a IL-12 related condition in a cell, tissue, organ or animal, comprising

• (a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:
• 7, 8, 9, 10, 11, or 12, with, or to, said cell, tissue, organ or animal.

A medical device, comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, wherein said device is suitable to contacting or administerting said at least one anti-p40 Ig derived protein by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A method for producing at least one isolated mammalian anti-p40 Ig derived protein having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said Ig derived protein.

At least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

An isolated nucleic acid encoding at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A composition comprising at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, and at least one pharmaceutically acceptable carrier or diluent.

An anti-idiotype antibody or fragment that specifically binds at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A method for diagnosing or treating a IL-12 related condition in a cell, tissue, organ or animal, comprising

• (a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:
• 7, 8, 9, 10, 11, or 12, with, or to, said cell, tissue, organ or animal.

A medical device, comprising at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, wherein said device is suitable to contacting or administerting said at least one anti-p40 Ig derived protein by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12.

A method for producing at least one isolated mammalian anti-p40 Ig derived protein that binds to the same region of a IL-12 protein as an Ig derived protein comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

• 7, 8, 9, 10, 11, or 12, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said Ig derived protein.

At least one isolated mammalian anti-p40 Ig derived protein, comprising at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9.

An isolated nucleic acid encoding at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9.

A composition comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9, and at least one pharmaceutically acceptable carrier or diluent.

An anti-idiotype antibody or fragment that specifically binds at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9.

A method for diagnosing or treating a IL-12 related condition in a cell, tissue, organ or animal, comprising

• (a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:
• 9, with, or to, said cell, tissue, organ or animal.

A medical device, comprising at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9, wherein said device is suitable to contacting or administerting said at least one anti-p40 Ig derived protein by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9.

A method for producing at least one isolated mammalian anti-p40 Ig derived protein having at least one human CDR, wherein said Ig derived protein specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:

• 9, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said Ig derived protein.

Any invention described herein.